drugset / Trial / NCT00620542

CRESTOR Athero Imaging Head to Head IVUS Study

NCT00620542

Phase 3 Completed 2333 enrolled AstraZeneca The Cleveland Clinic · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.

Timeline

Start
2008-01
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 80 mg Oral
Subject Rosuvastatin Small molecule 40 mg Oral